At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 45 enrolled
Drug / intervention
DFD-01 (betamethasone dipropionate) Spray, 0.05%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter Study of Patient-Reported Satisfaction Following Twice Daily Dosing With Betamethasone Dipropionate Spray, 0.05% in Subjects With Moderate Plaque Psoriasis
In Brief
A Phase 4 clinical trial evaluating DFD-01 (betamethasone dipropionate) Spray, 0.05% for Plaque Psoriasis. Completed, enrolled 45 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess clinical response and patient satisfaction when DFD-01 is used topically twice a day for moderate plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPlaque Psoriasis
CountriesUnited States
CollaboratorsProsoft Clinical
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartFeb 2016
First PostedApr 2016
Primary CompletionJul 2016
Study CompletionAug 2016
TodayJul 2026
First PostedApr 25, 2016
Enrollment StartFeb 1, 2016
Primary CompletionJul 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.2 years ago
Interventions
DFD-01 (betamethasone dipropionate) Spray, 0.05%drug
DFD-01 (betamethasone dipropionate) Spray, 0.05% to be applied twice daily on the affected areas (avoiding the face, scalp, groin, axillae and other intertriginous areas) for 28 days.